This chapterized activity features 5 leading international experts who address the complex interrelationship of type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). In this “hot topic” program, the discussants review the release of recent data from clinical trials of adjunctive medicines with statin therapy focused on CV event risk reduction in patients with diabetes. The faculty also examine global guidelines and recommendations that address risk factor assessment and management. The use of LDL-lowering and adjunct agents will be explored, along with the new role of omega-3 fatty acids in current management algorithms. Authoritative practical considerations on lipid management in diabetes are discussed, as well as cardiovascular management during the COVID-19 pandemic. A pdf of the slides from this activity is available in the Resources section.